Cedric Francois Sells 13,551 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 13,551 shares of the business’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $412,356.93. Following the transaction, the chief executive officer now directly owns 418,519 shares in the company, valued at approximately $12,735,533.17. The trade was a 3.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Cedric Francois also recently made the following trade(s):

• On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total transaction of $179,969.72.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Stock Down 2.5 %

Apellis Pharmaceuticals stock opened at $30.00 on Friday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals, Inc. has a one year low of $24.34 and a one year high of $71.90. The company has a 50-day simple moving average of $32.08 and a 200-day simple moving average of $33.18. The firm has a market capitalization of $3.73 billion, a P/E ratio of -14.78 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.17) EPS. As a group, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D raised its stake in shares of Apellis Pharmaceuticals by 6.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock valued at $1,735,000 after purchasing an additional 2,820 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Apellis Pharmaceuticals by 42.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after buying an additional 39,931 shares in the last quarter. Amalgamated Bank lifted its stake in shares of Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after acquiring an additional 359 shares during the period. Xponance Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 7.6% in the second quarter. Xponance Inc. now owns 13,773 shares of the company’s stock valued at $528,000 after acquiring an additional 968 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Apellis Pharmaceuticals during the second quarter valued at approximately $2,350,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on APLS. Wells Fargo & Company cut their price target on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Piper Sandler dropped their price target on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. Scotiabank reduced their price objective on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).